Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02509156 : Stem Cell Injection in Cancer Survivors
PhasePhase 1
AgesMin: 18 Years Max: 79 Years
Eligibility
Inclusion Criteria

To participate, a subject MUST:

1. Be ? 18 and < 80 years of age

2. Be a cancer survivor with diagnosis of AIC

3. Have an LVEF ? 40% by cMRI

4. Be in NYHA class II-III

5. Have received the initial diagnosis of AIC at least six months earlier and be on
stable, optimally-tolerated therapy with beta-blockers, ACE inhibitors/ARBs, and/or
aldosterone antagonists for 1 month, unless contraindicated

6. Have a period of at least two years of clinical cancer-free state* and low likelihood
of recurrence (a five-year risk of recurrence estimated at 30% or less), as
determined by an oncologist, based on tumor type, response to therapy, and negative
metastatic work-up at the time of diagnosis (*exceptions to this are carcinoma in
situ or fully resected basal and squamous cell cancer of the skin.)

7. Be a candidate for cardiac catheterization

Exclusion Criteria

To participate, a subject MUST NOT HAVE:

1. A life expectancy <12 months

2. A CT scan or baseline cardiac MRI showing new tumor or suspicious lymphadenopathy
raising concern of malignancy

3. Presence of CAD as determined via imaging within 12 months prior study enrollment
(e.g. a rest and stress nuclear scan (SPECT/PET/CT), a stress echocardiogram, stress
MRI, or cardiac computed tomography angiography (CCTA). If coronary arteriogram,
within the last 24 months)

4. Had a previous myocardial infarction

5. A history of radiation therapy AND evidence of constrictive physiology and/or
evidence of other patterns of non-ischemic cardiomyopathy on cardiac MRI (e.g.,
amyloidosis, sarcoidosis, hemochromatosis, pure radiation-induced cardiomyopathy,
etc.) not consistent with AIC being the dominant etiology of heart failure

6. Valvular heart disease including 1) mechanical or bioprosthetic heart valve; or 2)
severe valvular (any valve) insufficiency/regurgitation within 12 months of consent.

7. Aortic stenosis with valve area ? 1.5cm2

8. A history of LV reduction surgery or cardiomyoplasty

9. Evidence of cardiogenic shock

10. A history of ischemic or hemorrhagic stroke within 90 days of baseline testing

11. Liver dysfunction during baseline testing, as evidenced by enzymes (e.g., AST, ALT,
alkaline phosphatase) greater than 3 times upper limit of normal

12. Diabetes with poorly controlled blood glucose levels (HbA1c > 8.5%)

13. An underlying autoimmune disorder or current immunosuppressive therapy (e.g., chronic
corticosteroid, rheumatologic or immune modulating therapy) or likelihood of use of
immunosuppressive therapy during participation in the trial

14. A baseline eGFR <35 ml/min/1.73m2

15. A contrast allergy that cannot adequately be managed by premedication

16. A history of organ or cell transplantation, except for transplantation of bone, skin,
ligament, tendon, or cornea

17. A hematologic abnormality during baseline testing as evidenced by hemoglobin < 9
g/dl; hematocrit < 30%; absolute neutrophil count < 2,000 or total WBC count more
than 2 times upper limit of normal; or platelet values < 100,000/ul

18. Evidence of active systemic infection at time of study product delivery

19. HIV and/or active HBV or HCV

20. Coagulopathy (INR > 1.5) not due to a reversible cause (e.g., warfarin and/or Factor
Xa inhibitors) (see Section 6.4 re: injection procedure and anticoagulation therapy)
Note: Subjects who cannot be withdrawn from anticoagulation will be excluded.

21. Presence of LV thrombus

22. Presence of a pacemaker and/or ICD generator with any of the following
limitations/conditions:

- manufactured before the year 2000

- leads implanted < 6 weeks prior to consent

- non-transvenous epicardial or abandoned leads

- subcutaneous ICDs

- leadless pacemakers

- any other condition that, in the judgment of device-trained staff, would deem an
MRI contraindicated

23. Pacemaker-dependence with an ICD (Note: pacemaker-dependent candidates without an ICD
are not excluded)

24. A cardiac resynchronization therapy (CRT) device implanted < 3 months prior to
consent

25. Other MRI contraindications (e.g. patient body habitus incompatible with MRI)

26. An appropriate ICD firing or anti-tachycardia pacing (ATP) for ventricular
fibrillation or ventricular tachycardia within 30 days of consent

27. Ventricular tachycardia ? 20 consecutive beats without an ICD within 3 months of
consent, or symptomatic Mobitz II or higher degree atrioventricular block without a
functioning pacemaker within 3 months of consent

28. A history of drug abuse (use of illegal "street" drugs except marijuana, or
prescription medications not being used appropriately for a pre-existing medical
condition) or alcohol abuse (? 5 drinks/day for ? 3 months), or documented medical,
occupational, or legal problems arising from the use of alcohol or drugs within the
past 24 months

29. Cognitive or language barriers that prohibit obtaining informed consent or any study
elements (interpreter permitted)

30. Participation (currently or within the previous 30 days) in a cardiac related
investigational therapeutic (including stem cell based therapies) or device trial

31. Pregnancy, lactation, plans to become pregnant in the next 12 months, or is unwilling
to use acceptable forms of birth control during study participation

32. Any other condition that, in the judgment of the Investigator or Sponsor, would be a
contraindication to enrollment, study product administration, or follow-up
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02509156      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740